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Herpesvirus papio (HVP) is a lymphotropic virus of baboons which is related to Epstein-Barr virus (EBV)
and produces latent infection. The nucleotide sequence of the 5,775-base-pair (bp) EcoRI K fragment of HVP,
which has previously been shown to confer the ability to replicate autonomously, has been determined. Within
this DNA fragment is a region which bears structural and sequence similarity to the ori-P region of EBV. The
HVP ori-P region has a 10- by 26-bp tandem array which is related to the 20- by 30-bp tandem array from the
EBV oni-P region. In HVP there is an intervening region of 764 bp followed by five partial copies of the 26-bp
monomer. Both the EBV and HVP 3' regions have the potential to form dyad structures which, however, differ
in arrangement. We also demonstrate that a transcriptional enhancer which requires transactivation by a
virus-encoded factor is present in the HVP ori-P.
The episomal form of the Epstein-Barr virus (EBV) ge-
nome is thought to be the molecular basis for latent EBV
infection (1, 25, 26, 28), but the mechanism of the persis-
tence of the episome in cells was until recently largely
unknown. EBV episomes are unit-length supercoiled intra-
cellular EBV genomes found in non-virus-producing cells at
copy numbers that are both limited and fixed in successive
cell generations (19, 24, 28). The episomes are intranuclear
and in a nucleosomal arrangement (37) and are thought to be
replicated by host rather than viral polymerase (5, 28).
Transcripts found spanning the fused genomic termini in
infected cells indicate that at least one EBV gene in the
episomal form is transcribed (17).
Replication of EBV episomes requires two cis-acting
elements in the BamHI-C region of the genome, which
constitute the plasmid origin of replication (ori-P) (35, 38, 40,
41). The cis-acting elements consist of a series of repeat units
located at the 5' end of ori-P separated by intervening
sequence from an area of dyad symmetry located at the 3'
end (20), where replication is initiated (8). Transactivation
by the EBNA-1 protein is required for the episomal mainte-
nance function of ori-P, as well as for a transcriptional
enhancer activity that has been identified within the 5'
element of ori-P (34).
We have analyzed herpesvirus papio (HVP), a lymphotro-
pic virus of baboons that is able to immortalize both human
and baboon B lymphocytes in vitro (31), to generalize these
mechanisms of episomal maintenance to another virus. HVP
is similar structurally and biologically to EBV, but on the
genomic level the viruses share only 40% homology (7, 10,
18). A region in HVP with sequence and functional homol-
ogy to the EBV ori-P has been identified which requires a
trans-acting function analogous to that found in EBV (29,
30). This transactivation can be supplied by either EBNA-1
or HVP protein, presumably HVP nuclear antigen (27).
Conversely, constructs containing the EBV ori-P can be
maintained in HVP-infected cells, although HVP nuclear
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antigen and EBNA-1 are not identical proteins (6). We
therefore sequenced the HVP ori-P to identify and compare
the essential conserved features of the two origins of repli-
cation. We also demonstrate that a transcriptional enhancer,
requiring transactivation by a virus-encoded factor, exists
within the HVP ori-P.
MATERIALS AND METHODS
Sequencing of the 5,775-base-pair (bp) HVP EcoRI K
fragment. The HVP EcoRI K fragment was subcloned and
sequenced as described by Bankier et al. (3). The sequence
was compiled and analyzed with programs described by
Staden (38).
Cell lines. B95-8, an EBV-productive marmoset B-cell line
(21); Raji, a human Burkitt's lymphoma-derived line latently
infected with EBV; Loukes, an EBV genome-negative hu-
man B-cell line; and 594-S (32), a baboon B-cell line produc-
tively infected with HVP, were maintained at 37°C in RPMI
1640 medium supplemented with 10% fetal calf serum, 100 U
of penicillin per ml, and 100 ,ug of streptomycin per ml in a
5% CO2 environment.
DNA transfections. Plasmid DNA was amplified in Esche-
richia coli and purified over two sequential cesium chloride
gradients. For each sample, 10 ,ug of plasmid DNA was
electroporated (23) into 107 cells at 1,500 V. Cells were then
suspended in 10 ml of RPMI 1640 medium supplemented
with 10% fetal calf serum and incubated for 48 h at 37°C in
5% CO2-
Chloramphenicol acetyltransferase (CAT) assays. Extracts
were prepared by washing cell pellets twice in phosphate-
buffered saline solution, suspending them in 200 p.1 of 0.25 M
Tris hydrochloride (pH 7.5), and freeze-thawing four times.
Protein determinations were made by using the Bio-Rad
Laboratories protein assay. All samples in each assay con-
tained equal amounts of protein from extracts of 107 cells.
Reactions were carried out as described previously (9) by
incubating each sample with acetyl coenzyme A and
[14C]chloramphenicol at 37°C for 60 min. Acetylated reac-
tion products were separated by thin-layer chromatography,
visualized by autoradiography, and quantitated by scintilla-
tion counting.
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FIG. 1. HVP and EBV ori-P regions. (A) Map of sequence features in the HVP EcoRI K fragment. The following features are in common
with EBV. Open reading frames and direction of transcription are denoted by black arrows. Bases 1 to 326 correspond to the 3' end of the
EBV BNRF1 reading frame. Bases 3770 to 4285 correspond to the EBV BCRF1 reading frame. EBER 1 and 2 are denoted by gray arrows
and are found at bases 1235 to 1424 and 1549 to 1717, respectively. The ori-P region encompasses positions 2084 to 3220. (B) Organization
of ori-P regions of EBV and HVP. The ori-P of each virus has the general structure of an array of monomer units, followed by an intervening
sequence of variable length, followed by four or five partial copies of the monomer unit which has the potential to form a large dyad. HVP
has an additional two partial copies of the monomer unit at the 5' end of the intervening sequence. (C) Comparison of 5' array monomer
consensus sequences of EBV and HVP. Sequence common to EBV and HVP is underlined (match in 16 of 19 bp). Arrow indicates dyad of
symmetry in each monomer unit. HVP consensus sequence was generated by considering only the sequences in the 5' arrays. The EBV
consensus sequence is taken from Fig. 6 of Lupton and Levine (20).
Plasmid constructions. pA1OCAT-680-1 and pA1OCAT-680-
2 were generated by cloning a 680-bp DNA fragment from
the HVP ori-P region, containing five of the repeat units as
well as two imperfect repeat units from the intervening
sequence, in both orientations, into the BamHI site of
pA1OCAT (see Fig. 4). The pA1OCAT vector contains the
CAT gene under the control of the simian virus 40 (SV40)
early promoter but lacks the SV40 enhancer sequences (16).
pCAT3M680-1 and pCAT3M680-2 were generated by clon-
ing the same 680-bp fragment, in both orientations, into the
BglII site of the promoterless CAT vector pCAT3M (see Fig.
4) (15). A second construct containing the entire motif of 10
repeat units was also cloned into pA1OCAT.
RESULTS
Nucleotide sequence of the HVP EcoRI K fragment. The
nucleotide sequence of the HVP EcoRI K fragment was
determined. It is 5,775 bp in length and is homologous to
sequences within the EBV BamHI C fragment (nucleotides
5367 to 11635 of the EBV sequence). Within this region of
the EBV genome there are five notable features: the 3'
portion of the BNRF1 reading frame; the entire BCRF1
reading frame; two polymerase III RNAs, EBER 1 and 2;
and the ori-P region (Fig. 1A and B). All of these features are
also found in the HVP EcoRI K fragment. The HVP EBER
1 and 2 are 78 and 66% homologous, respectively, to the
EBV EBER sequence reported by Howe and Shu (11).
Although the HVP EcoRI K fragment and its corresponding
EBV sequence are homologous for most of their lengths,
especially in these functional domains, there are regions in
which there is no obvious sequence homology. Table 1
contains a summary of the degree of homology between the
EBV and HVP sequences.
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TABLE 1. Sequence homology between the HVP EcoRI K
fragment and the homologous region in EBV as a function
of nucleotide position
HVP positions" EBV positionsb % Homologyc EBV featured
1-326 5367-5692 73 BNRF1
327-754 5693-6153 70 3' to BNRF1
755-1050 6154-6406 NSH
1051-1234 6407-6628 56 5' to EBER 1
1235-1424 6629-6795 80 EBER 1
1425-1548 6796-6955 60 Intervening
1549-1717 6956-7128 66 EBER 2
1718-1810 7129-7206 54 3' to EBER 2
1811-1990 7207-7302 NSH
1991-2083 7303-7449 58 5' to array
2084-2347 7450-8032 84 10- by 26-bp array
2348-2621 8033-8554 NSH Intervening
2622-3090 8555-9032 50 Intervening
3134-3224 9033-9133 70 3' dyad motif
3225-3611 9134-9515 NSH
3612-3769 9516-9674 64 5' to BCRF1
3770-4285 9675-10187 82 BCRF1
4286-4595 10188-10491 73 3' to BCRF1
4596-4895 10492-10765 NSH
4896-577 10766-11635 69
a Refers to the nucleotide coordinate within the HVP EcoRI K fragment.
b Refers to the nucleotide ccordinate within the published B95-8 EBV
sequence (2).
c Homology values within the 10- by 26-bp array refer to a match in 16 of 19
bp between the consensus EBV and consensus HVP monomer sequences.
NSH, No significant homology found.
d Features are those previously described in the EBV B95-8 sequence.
EBV ori-P. Although the general format of the HVP ori-P is
similar to that of the EBV ori-P, there are considerable
differences between the two ori-Ps on the nucleotide level.
To facilitate the description of the HVP ori-P region, a brief
review of the structural features of the EBV ori-P is in order.
The 5' end of the EBV ori-P region has 20 copies of a 30-bp
unit in a tandem array. Approximately 987 bp downstream of
this 20- by 30-bp tandem array are four partial copies of the
30-bp monomer. Dyad structures can be proposed in this
downstream region, with monomers and surrounding se-
quence contributing to the structure (14, 20, 33).
The HVP ori-P is similar in its general structure, with the
following specific differences (Fig. 1B). The 5' end of the
HVP ori-P region has 10 imperfect and/or partial copies of a
26-bp unit in tandem array. This 26-bp monomer is related to
the EBV 30-bp monomer (Fig. 1C; see below). Approxi-
mately 764 bp downstream of the 10- by 26-bp array are five
partial copies of the 26-bp unit. The intervening 764-bp
sequence harbors two imperfect copies of the 26-bp mono-
mer, which are not found in the EBV ori-P. As in EBV, the
3' sequence of the HVP ori-P has the potential to form a
large dyad (80 bp), but unlike in EBV, only monomer
sequence contributes to the proposed dyad structure (Fig.
2).
Comparison of the EBV and HVP ori-P repeat units. The
30-bp EBV repeat monomer and the HVP 26-bp repeat
monomer are homologous for 19 bp. A comparison of a
consensus sequence of the repeat unit of each virus reveals
a match in 16 of 19 bp (Fig. 1C). If the first base of these
consensus sequences is discarded, an imperfect 9- by 9-bp
dyad of symmetry can be formed, as previously noted for
EBV. When only the HVP repeat unit is considered, this
dyad can be extended to an imperfect 13- by 13-bp dyad,
which comprises the entire 26-bp unit. In EBV the dyad
cannot be extended. Thus in the HVP ori-P, all 26 bp of each
monomeric unit can form an imperfect dyad, whereas in
EBV only 18 bp of each 30-bp monomeric unit can form a
dyad.
Examination of the pattern of polymorphisms within the
individual EBV repeat units reveals an imperfect duplication
of a putative ancestral 10- by 30-bp array leading to the
present-day 20- by 30-bp array. In this respect, the 10- by
26-bp HVP array would be more similar to the ancestral
EBV array in size.
Toward defining a recognition site for the HVP trans-acting
protein. The HVP ori-P, like the EBV ori-P, requires acti-
vation by a trans-acting protein. Since transactivation ap-
pears to be brought about by actual binding of EBNA-1 to
the repeat units (22, 33), the variations tolerated within the
repeat monomers may be useful in further defining the
sequence that the HVP transactivator recognizes. When
only the 5' tandem array of each virus is considered, 19 bp in
the monomer unit is shared by both viruses (Fig. 3). Addi-
tionally, the portion of the monomer unit that is common
between the 5' and 3' arrays within both viruses is the last 18
bp of the above-mentioned 19 bp. This 18-bp sequence is
palindromic and contains the 12-bp core EBNA-1-binding
sequence (12). A consensus sequence, GGRTAGYMTRYR
CTRYCC, in which R is a purine, Y is a pyrimidine, and M
EBV
A B C D
ACCCTTTTAC TAACCCTAAT TCGATAGCAT ATGCTTCCCG TTGGGTAACA TATGCTATTG AATTAGGGTT AGTCTGGATA GTATATACTA CTACCCGGGA AGCATATGCT ACCCGTTTAGGG
11II llllll} 1l 1 I1 l IIIlllI I lllI ll lI 1H1I 11 lI lllI ll 11 II
GGACAGCACA TACTGCCTCG CAGATAGCAT ATACCGCCGG CATGATAGCA TATGCTACCC AG ........ ... ATGGATA GCATACGCTA CCTCCCGGGT AGTATTTGCT ATCCGGGTAAGG
3113 3134 3155 3177 3198
HVP
FIG. 2. Sequence comparison of the 3' dyad regions of HVP and EBV. The upper nucleotide sequence is EBV; the lower sequence is
HVP. Labeled overlined and underlined regions (A to D) indicate copies of the monomer unit. The regions of dyad symmetry are indicated
by arrows. Although other EBV dyad structures are possible, that proposed by Lupton and Levine (20) is shown here. The indicated HVP






























































FIG. 3. Comparison of the monomer sequences in the HVP and EBV ori-P regions. The consensus sequence is generated by noting the
most common nucleotide at that position. A consensus was generated for the 5' and 3' arrays for each virus. Nonconsensus nucleotides
appearing in more than one monomer are denoted by lowercase letters beneath the consensus nucleotides. Aligned below the consensus
sequence are the individual complete and partial monomer sequences, with differences indicated. Names appear next to each monomer. HVP
monomers were identified by searching the HVP EcoRI K fragment for a match in 9 of 12 bp by the sequence TAGCATATGCTA. All but
the monomer at position 3113 were identified by this method. The 3113 monomer was visually identified. EBV monomers were taken from
Fig. 6 of Lupton and Levine (20). (Inset) Alignment of common nucleotides in the consensus sequences from the 5' and 3' arrays is shown.
Minor variants are denoted by lowercase letters beneath the respective consensus sequence. R indicates a purine (A or G).
is A or C, can be derived from the EBV and HVP 18-bp
palindrome.
Demonstration of a transcriptional enhancer element within
the HVP ori-P. The EBV ori-P contains a transcriptional
enhancer (34, 41). To determine whether enhancer activity
could also be localized to the 5' repeat element of the HVP
ori-P, constructs were made containing HVP repeated units
linked to the CAT reporter gene. A 680-bp fragment contain-
ing five of the repeat units and the two imperfect units from
the intervening sequence was cloned in both orientations
downstream of the CAT gene in the pAjOCAT vector (Fig.
4). This 680-bp fragment was able to enhance CAT expres-
sion from the SV40 early promoter by approximately 12-fold
in 594-S cells expressing HVP gene products and by 9-fold in
B95-8 cells expressing EBV gene products but was unable to
enhance expression in EBV- or HVP-negative cells (Fig. 5
and Table 2).
To demonstrate that the enhancement observed was not
due to promoter activity intrinsic to the 680-bp fragment, it
was cloned in both orientations into the promoterless CAT
vector pCAT3M (Fig. 4). No enhancement was observed in
any of the cell lines tested. Representative assays are shown
in Fig. 5.
Additional pAjOCAT constructs consisting of a 1,750-bp
fragment (HVP EcoRI-K positions 1688 to 2438 in both
orientations), which included all 10 repeat units in the motif
but omitted the 2 repeats in the intervening sequence, were
also tested. When they were assayed simultaneously in
either EBV-infected or HVP-infected cells, the CAT activity
TABLE 2. Quantitation of enhancement of CAT expression
in different cell lines
Virusa Fold enhancementb
Cell line
EBV HVP 680-1 680-2
Loukes - - 1.7 (8) 0.7 (7)
B95-8 + - 9.3 (6) 8.9 (5)
594-S - + 13.9 (4) 11.8 (5)
a The presence (+) or absence (-) of viral genomes in each cell line is
indicated.
b Ratio of the percent acetylation per microgram of extract in samples
containing the 680-bp insert to the percent acetylation in samples containing
the pA1o CAT vector alone, expressed as the average of the number of
determinations indicated in parentheses. 680-1 and 680-2 designate the two
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FIG. 4. Plasmid constructions containing a portion of the HVP repeat motif. pAjOCAT-680-1 and pAjOCAT-680-2 indicate the two
orientations in which the 680-bp fragment was cloned into the BamHI site directly downstream of the CAT gene in the vector pAjOCAT. The
position of the SV40 early promoter is indicated (0). pCAT3M680-1 and pCAT3M680-2 indicate the same 680-bp fragment cloned in both
orientations directly upstream of the CAT gene in the promoterless CAT expression vector pCAT3M. The region of the HVP ori-P included
in the 680-bp fragment is shown (- --).
of these constructs was equivalent to or stronger than that of
the original construct shown in Fig. 4 (data not shown).
DISCUSSION
The HVP ori-P, first defined as the functional analog of the
EBV ori-P (29), is shown in this work to be similar structur-
ally to the EBV ori-P. Both ori-Ps have the same general
format and many special features in common on the basis of
sequence. However, there are differences between the two
ori-Ps that may imply what is necessary for function.
The HVP ori-P consists in essence of two elements, a 5'
array consisting of 10 tandem copies of a 26-bp unit and,
approximately 750 bp downstream in the genome, 5 addi-
tional imperfect and partial copies of the monomer unit.
EBV ori-P has the same general structure, although it is
larger. EBV ori-P has 20 tandem copies of a 30-bp monomer
unit, which is related to the 26-bp HVP monomer unit.
Approximately 1,000 bp downstream of this array in EBV
are four additional imperfect and partial copies of the 30-bp
monomer unit. Dyad structures can be proposed in this 3'
region (13), which have been hypothesized to be important in
ori-P function (20). Similar although not identical dyad
structures can be proposed for the 3' region of the HVP
ori-P.
A comparison of the two viral ori-P regions leads us to
propose that the following general features are important for
function. The 5' tandem array does not need to be larger than
10 monomer units, as evidenced by the size of the HVP 5'
tandem array. This conclusion is corroborated by recent
work (4, 39) in which deletion analysis of the EBV 5' tandem
array indicates that at least six or seven monomer units are
needed for ori-P function. However, since the monomers act
cooperatively rather than additively to bind EBNA-1 pro-
tein, less than a minimum number of binding sites does not
simply reduce efficiency but abolishes function.
The intervening sequence between the 5' tandem array
and the 3' array is thought to be of lesser importance in the
EBV ori-P, because ori-P function is preserved in constructs
in which this sequence is largely deleted. Presumably, the
intervening DNA plays a minimal role in ori-P function by
contributing to the overall structural arrangement, rather
than having a direct sequence effect. The sequences of the
HVP and EBV intervening DNA are quite different, except
for the increasing homology (50 to 60%) of the last 400 bases
approaching the 3' dyad.
The 3' arrays or dyad regions of EBV and HVP have four
and five partial copies of the monomer units, respectively.
The partial copies are homologous to each other. This region
has recently been proposed to function as the site of initia-
tion of plasmid replication in EBV (8), and we can safely say
that only partial copies of the monomer unit are needed for
function. The role of dyad formation is less clear, although
we have shown that the area in which these structures form
is spared of nucleosomes during reassembly in vitro, which
may facilitate initiation of replication in latent infection (36).
Both EBV and HVP have the potential to from these
structures.
We have also demonstrated the existence of a transcrip-
tional enhancer element within the ori-P region of HVP.
Enhancement was observed in the presence of five perfect
and two imperfect repeats of the monomer unit, which is the
minimal number of copies required for enhancement in EBV
(4, 39). In other constructs containing 10 repeats, the level of
enhancement was greater. Enhancer activity was most pro-
nounced in the HVP-infected cell line 594-S, which was
expected since these cells presumably produce an authentic
HVP transactivator analogous but not identical to EBNA-1.
Enhancement was also observed, to a lesser degree, in the
EBV-infected cell line B95-8, suggesting that the HVP
enhancer can be transactivated by an EBV gene product.
However, we have not identified the transactivator gene or
genes, nor have we explored whether lymphoid cell factors
might contribute to HVP enhancer function.
Our results clearly demonstrate that the HVP ori-P, like
its EBV counterpart, requires transactivation by factors
present in both EBV- and HVP-infected cells for both
enhancer and replicative functions (29). Since binding of the
EBNA-1 protein to the EBV repeat monomers appears to be
inseparable from the transactivator function, and since an
EBNA-1 fusion protein binds specifically to the HVP ori-P
(C. J. Sexton, J. Griffith, and J. S. Pagano, unpublished
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FIG. 5. HVP enhancer function shown through CAT expression in different cell lines. (A) Assay for promoter activity. pCAT3M680-1 and
pCAT3M680-2 were transfected into the cell lines shown and assayed for CAT activity. (B) Assay for enhancer activity. pA1OCAT-680-1 and
pA1OCAT-680-2 were transfected into the cell lines shown and assayed for CAT activity. pRSV-CAT contains the CAT gene under the control
of the RSV enhancer. pA1OCAT contains the CAT gene under the control of the SV40 early promoter but lacks enhancer sequences.
EBNA-1-like protein. EBNA-1 is likely to be a less efficient
transactivator of the HVP enhancer, and there is evidence
that the EBNA-1 fusion protein binds to the HVP ori-P with
a lower specificity (Sexton et al., unpublished data). This
decrease in efficiency may be accounted for by subtle
differences in the binding domains of the two proteins or by
minor variations in the binding sites between the two viral
ori-Ps. Although the consensus binding sequence for EBNA-
1 has been defined as a 12-bp palindrome (33), our examina-
tion of the sequence of the repeat monomers revealed an
18-bp palindromic sequence conserved between the two
viruses. The 12-bp EBNA-1-binding sequence is located
within this 18 bp.
In EBV, only 19 bp of the repeat monomer is conserved in
both the 5' and 3' repeat elements. This 19-bp sequence
encompasses an 18-bp palindrome conserved in EBV and
HVP. Conservation of the 18-bp palindrome in both the EBV
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sequence flanking the 12-bp EBNA-1-binding site may play a
role in recognition by EBNA-1 or an EBNA-1-like HVP
protein. The different variations tolerated in the repeat
monomers within the HVP and EBV ori-Ps may correlate
with the different binding and transactivation efficiencies of
the two viral proteins.
Thus, the HVP ori-P exhibits all of the structural and
functional components of the EBV ori-P, although the
initiation and termination points for DNA replication have
yet to be demonstrated in HVP.
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